Introduction {#Sec1}
============

*Chlamydia trachomatis* is an important cause of sexually transmitted infections (STIs) in women, which may lead to pelvic inflammatory disease, tubal infertility, ectopic pregnancy, and chronic abdominal pain \[[@CR1]--[@CR4]\]. Chlamydial infection during pregnancy may in addition influence pregnancy outcomes leading to premature rupture of membranes, prematurity, low birthweight and perinatal mortality, and cause neonatal conjunctival and respiratory infection \[[@CR5]--[@CR7]\]. The literature regarding the detrimental effects of *C. trachomatis* infection on pregnancy outcome, however, yields conflicting results that seem primarily due to differences in study design, population and microbiological tests employed \[[@CR8]--[@CR24]\].

Screening for *C. trachomatis* in pregnant women has revealed prevalence rates varying from 0 to 37% and various associated risk factors for infection including in particular age and socio-economic status \[[@CR25]--[@CR27]\].

In the Netherlands, a chlamydial prevalence of 2.5% was reported in women \[[@CR28]\]. However, prenatal screening for *C. trachomatis* is not routine obstetrical practice in the Netherlands and data on pregnant women and pregnancy outcome are lacking.

The objective of this study was to assess the prevalence of *C. trachomatis* infection in pregnant women and to investigate the association of chlamydial infection with the risks of preterm delivery and low birthweight or being small for gestational age.

Methods {#Sec2}
=======

Design {#Sec3}
------

This *Chlamydia trachomatis* study was embedded in the Generation R Study, which is a population-based, non-interventional, prospective cohort study designed to identify early environmental and genetic determinants of growth, development and health of children, starting from foetal life until adolescence \[[@CR29], [@CR30]\]. Pregnant women, attending one of the participating midwifery practices or antenatal clinics and expected to deliver in Rotterdam, were eligible for the study. Regular health care workers (midwives, obstetricians) informed the women about the study. Most women spoke Dutch, otherwise the study was explained and questionnaires were provided in their native language. Enrolment was scheduled in early pregnancy (gestational age \< 18 weeks) at the first routine foetal ultrasound examination, but was allowed until delivery. Women scheduled for termination of pregnancy and women with a miscarriage or perinatal death prior to or at the first ultrasound were not included. Generation R started in 2002; the Chlamydia sub-study was between February 2003 and January 2005**.**

Risk factors {#Sec4}
------------

Data were obtained using confidentially administered standardized questionnaires at the time of inclusion. Unanswered questions were registered as missing data. Maternal age was defined as age at enrolment. Ethnicity was defined according to the classification of Statistics Netherlands \[[@CR30]\]. Most women were Dutch (49%), Surinamese (9%), Turkish (9%) or Moroccan (7%). Educational levels of participating women were defined in groups by highest attained education (primary school, secondary school, higher education). Marital status was defined as married if married or living together in partnership. Further information was obtained regarding gravidity, number of sexual partners in the year prior to pregnancy, history of an STI, and use of cigarettes, alcohol and drugs.

Microbiological diagnosis {#Sec5}
-------------------------

Women provided a first-void urine specimen to test for *C. trachomatis* at enrolment. Urines were stored at 4°C, transported the same or following working day, and processed within 24 h of receipt by the laboratory. DNA was isolated from pooled urine specimens using the MagNA Pure LC Bacterial DNA isolation Kit III (Roche Molecular Systems, Alameda, USA) and amplified by polymerase chain reaction (PCR) (Cobas Amplicor, Roche Molecular Diagnostics, Branchburg, USA) \[[@CR31]\]. In brief, pools were made of five individual urines by adding 200 μl of each urine into one tube. From each pool the full 1,000 μl were taken, and centrifuged for 10 min. Subsequently, 900 μl were removed and the pellet was resuspended in 100 μl of the remaining supernatant, mixed with 130 μl lysis buffer and 20 μl proteinase K, incubated for 10 min, and thereafter denatured for 10 min. Finally, DNA was isolated in the automated MagNA Pure LC using a sample volume of 250 μl and an elution volume of 100 μl. Then, 25 μl was used for PCR. Urines from positive pools were individually re-tested and reported as negative or positive.

Pregnancy outcomes {#Sec6}
------------------

Information about pregnancy outcomes (miscarriage, perinatal death, gestational age, birthweight) was obtained postnatally from midwives and hospital registries. Gestational age was established by foetal ultrasound examination instead of last menstrual period. Establishing gestational age by using the first day of the last menstrual period is not reliable for a variety of reasons including the large number of women who do not know their exact date, have irregular menses or amenorrhoea, use oral contraceptives or bleed in early pregnancy. Establishing gestational age by foetal ultrasound can overcome these problems. Foetal ultrasound was performed by regular health care providers at each prenatal visit, which were planned in early pregnancy (gestational age \< 18 weeks), mid-pregnancy (gestational age 18--25 weeks) and late pregnancy (gestational age ≥ 25 weeks). The individual time scheme of assessments depended on the specific gestational age at enrolment. Pregnancy dating-curves were derived in a subsample of the Generation R study cohort including subjects with complete data on both the first day of the last menstrual period and crown-rump length or biparietal diameter. Subsequently, gestational age at prenatal enrolment and, as a consequence, at delivery was retrospectively established by crown-rump length or biparietal diameter measured in early pregnancy or mid-pregnancy (30). Preterm birth was defined as delivery at a gestational age of less than 37 weeks, with subgroups of gestational ages less than 32 weeks and less than 35 weeks. Low birthweight was defined as weight below 2,500 g, small for gestational age (SGA) as birthweight less than 2 standard deviation scores (SDSs) below the mean for gestation. Birthweight measurements were converted into gestational age adjusted SDS \[[@CR32]\].

Ethical aspects {#Sec7}
---------------

The *C. trachomatis* study was embedded within the framework of Generation R \[[@CR29], [@CR30]\], which were both approved by the Medical Ethical Committee for Research on Human Subjects of the Erasmus MC, Rotterdam. Written informed consent was obtained from all participants. Generation R provided data anonymously.

Data analysis {#Sec8}
-------------

Associations of *C. trachomatis* infection during pregnancy with socio-economic and life style risk factors of women were assessed using multiple logistic regression models. Unequivocal confounders were selected based on previous studies. Associations for each risk factor were studied while adjusting for all other risk factors and the confounders alcohol, drugs and smoking. We imputated missing data in other risk factors and confounders with multiple imputations. Preterm birth was analysed using multiple logistic regression models. We adjusted for maternal age, ethnicity, gravidity, education, and smoking).

The Kaplan--Meier procedure was used to illustrate the proportion of women delivering at given gestational ages and the Breslow test to calculate the significance of the difference between gestational ages at delivery of chlamydia-positive and chlamydia-negative women.

The proportion of preterm delivery attributable to *C. trachomatis* in women in the total population was assessed using the population attributable fraction of risk (PAR) \[[@CR33]\]. The PAR was calculated with the observed relative risk (RR) and the population fraction with chlamydial infection (PF):$$\documentclass[12pt]{minimal}
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Birthweight as a continuous variable was analysed using multiple linear regression models; low birthweight and SGA with multiple logistic regression models. The latter were adjusted for known determinants of low birthweight (maternal age, ethnicity, gravidity), socio-economic status and life style related variables (education, smoking).

Measures of association are presented with 95% confidence intervals (CI).

Statistical analysis was performed using the Statistical Package of Social Sciences version 11.0 for Windows (SPSS Inc, Chicago, IL, USA). Data imputation was done with the *MI* procedure in SAS 9.13.

Results {#Sec9}
=======

Population for analysis {#Sec10}
-----------------------

During the study period Generation R enrolled 5,167 pregnant women (Fig. [1](#Fig1){ref-type="fig"}), of whom 4,676 women (90%) provided a urine sample and were enrolled in the Chlamydia sub-study. Of these, 621 urines could not be matched to the respective questionnaires in the database. Urine samples and data from 4,055 women were analysed for the prevalence and risk factors for *C. trachomatis* infection. Half the women were included within the first 14 weeks of their pregnancy, 95% within 22 weeks.Fig. 1Profile of the generation R sub-study on *Chlamydia trachomatis*

Prevalence {#Sec11}
----------

*Chlamydia trachomatis* was detected in 157 of 4,055 (3.9%) women. Age-specific prevalences were 13.5% in women age ≤ 20 years, 6.7% between 21 and 25 years, 3.3% between 26 and 30 years and 1.6% in women over 30 years. Prevalences were highest in Antillean (16.2%), Cape Verdean (10.8%) or Surinamese (9.1%) women, and women with low education (5.8%), single marital status (11.9%), first pregnancies (4.5%), multiple sexual partners (7.7%), or a history of an STI (6.3%) (Table [1](#Tab1){ref-type="table"}).Table 1Socio-economic and life style risk factors of *Chlamydia trachomatis* infection in pregnant women*Chlamydia trachomatis infection*Risk factorsNegativePositiveCrudeAdjusted*n* = 3,898*n* = 157 (%)OR (95% CI)OR (95% CI)\#Age groups (*n* = 4055) \< 2121734 (13.5)9.43 (5.6--15.8)\*\*1.79 (1.2--2.6)\*\* 21--2574153 (6.7)4.31 (2.7--6.8)\*\*1.29 (1.0--1.7) 26--30119441 (3.3)2.07 (1.3--3.4)\*\*0.89 (0.7, 1.2) \> 30174629 (1.7)1.001.00Ethnicity (*n* = 3730) Dutch174833 (1.8)1.001.00 Cape Verdean14918 (10.8)6.40 (3.5--11.6)\*\*1.54 (0.9--2.5) Antillean10921 (16.2)10.21 (5.7--18.2)\*\*2.27 (1.4--3.7)\*\* Surinamese31031 (9.1)5.30 (3.2--8.8)\*\*1.43 (1.0--2.1) Moroccan/Turkish61014 (2.2)1.22 (0.7--2.3)0.51 (0.3--0.9)\* Other (non-) western66819 (2.8)1.51 (0.9--2.7)0.68 (0.4--1.1)Education (*n* = 3656) Primary school38924 (5.8)3.32 (1.9--5.8)\*\*1.28 (0.9--1.8) Secondary school157379 (4.8)2.71 (1.8--4.2)\*\*0.93 (0.7--1.2) Higher education1,56229 (1.8)1.001.00Marital status (*n* = 3648) Not married47965 (11.9)5.88 (4.1--8.4)\*\*1.60 (1.3--2.0)\*\* Married3,03470 (2.3)1.001.00Gravidity \> 1 (*n* = 4011) No1,71981 (4.5)1.001.00 Yes2,13873 (3.3)0.72 (0.5--1.0)0.85 (0.7--1.0)Multiple sexual partners in year prior to pregnancy (*n* = 3289) No2,91899 (3.3)1.001.00 Yes25121 (7.7)2.47 (1.5--4.0)\*\*1.23 (0.7--2.2)History of STI (*n* = 3313) No2,778100 (3.5)1.001.00 Yes37025 (6.3)1.88 (1.2--3.0)\*\*1.35 (0.7--2.5) Do not know382 (5.0)1.46 (0.4--6.2)0.79 (0.3--2.2)Values are frequencies and odds ratios (95% CI), \* *P*-value \< 0.05, \*\* *P*-value \< 0.01\# Adjusted for all other risk factors, use of drugs, alcohol and smoking with multiple imputation of missing data in the other factors

Women with missing data on ethnicity, education and smoking had higher chlamydia rates than women with data recorded: 6.5% versus 3.6% (*P* = 0.01), 6.3% versus 3.6% (*P* = 0.01) and 4.8% versus 3.4% (*P* = 0.04), respectively. Women with missing data on other variables had not higher rates of chlamydial infection.

Risk factors {#Sec12}
------------

In the unadjusted analysis age below 30 years, Antillean, Cape Verdean and Surinamese ethnicity, education, single marital status, multiple sexual partners and history of an STI were significantly associated with chlamydial infection (Table [1](#Tab1){ref-type="table"}). In the adjusted analysis age below 21 years, Antillean ethnicity and single marital status remained risk factors for infection; other maternal factors were not independently associated. Moroccan or Turkish women had a lower risk.

Pregnancy outcomes {#Sec13}
------------------

Pregnancy outcomes are shown in Table [2](#Tab2){ref-type="table"}. Of 4,055 pregnancies 3,931 resulted in live singleton births and 34 in live twins. Women who gave birth to twins were more often chlamydia-positive than women who had singletons (*P* = 0.05). Miscarriage (*n* = 11) and perinatal death (33 stillbirth, 18 neonatal death) occurred in 1.5% pregnancies. These adverse events were not associated with chlamydial infection during pregnancy. Preterm delivery occurred in 190 women (4.9%) of which prematurity before 32 weeks (0.6%) and 35 weeks (1.6%) of gestation was significantly associated with chlamydial infection (Table [2](#Tab2){ref-type="table"}). No significant association was observed with low birthweight.Table 2Pregnancy outcomes of women and their association with *Chlamydia trachomatis* infectionOutcomes*Chlamydia trachomatis* infectionNegativePositivePercentage positive (95% CI)*P*-value\**All outcomes* (*n* = 4,055) All women enrolled3,8981573.9 (3.3--4.5)*Live pregnancy outcomes* (*n* = 4,055) Live singleton birth3,7801513.8 (3.2--4.4)1.0 (reference) Live twin birth30411.8 (0.3--21.9)0.05 Lost to follow up2627.1 (0.0--17.3)0.29*Adverse pregnancy outcomesDemise* (*n* = 4,055) Miscarriage11001.00 Perinatal death51000.27*Gestational age\*\** (*n* = 3,913) Term, ≥ 37 weeks3,5831403.8 (3.2--4.4)1.0 (reference) Prematurity, \< 37 weeks180105.3 (2.1--8.5)0.33 Prematurity, \< 35 weeks57710.9 (3.1--18.8)0.01 Prematurity, \< 32 weeks18418.2 (0.7--36.7)0.01*Birthweight\*\** (*n* = 3,913) ≥ 2,500 g3,5891403.8 (3.1--4.4)1.0 (reference) \< 2,500 g174105.4 (2.1--8.7)0.25\* *P*-value (Chi-square or Fishers exact test) for comparison of *Chlamydia trachomatis* prevalence with respective outcome categories of live singleton birth, gestational age ≥ 37 weeks, and birthweight ≥ 2,500 gram\*\* Including live singleton birth outcomes only

After exclusion of women who were lost to follow up, or who had twin pregnancies, a miscarriage or perinatal death, the effect of Chlamydia on gestational age and birthweight was further analysed for 3,913 women and neonates.

### Gestational age {#Sec14}

The distribution of gestational ages according to the maternal chlamydial status is shown in a Kaplan--Meier plot (Fig. [2](#Fig2){ref-type="fig"}). Chlamydia-positive women had a significantly shorter duration of gestation (P Breslow = 0.02).Fig. 2Kaplan-Meier analysis of duration of gestation at delivery in women with and without *Chlamydia trachomatis* infection

Unadjusted analysis (Table [3](#Tab3){ref-type="table"}) showed that chlamydia-positive women had a significantly higher risk of preterm delivery before 32 weeks compared to delivery at term (OR 5.69 \[95% CI 1.90, 17.03\]). After adjustment for maternal age, ethnicity, education, gravidity, and smoking a significant four-fold increased risk (OR 4.35 \[95% CI 1.3--15.2\]) remained. Chlamydia-positive women also had a significantly higher risk of preterm delivery before 35 weeks (OR 3.14 \[95% CI 1.4--7.0\]), which also remained after adjustment for the above-stated confounders (OR 2.66 \[95% CI 1.1--6.5\]). Chlamydia-positive women had no increased risk of preterm delivery before 37 weeks.Table 3Risk for preterm delivery among women with *Chlamydia trachomatis* infectionRisk for preterm delivery\< 32 weeks\< 35 weeks\< 37 weeks*n* = 22*n* = 64*n* = 190Unadjusted odds ratio*C. trachomatis* infection5.69 (1.9--17.0)\*\*3.14 (1.4--7.0)\*\*1.42 (0.7--2.8)Adjusted odds ratio^\#^*C. trachomatis* infection4.35 (1.3--15.2)\*2.66 (1.1--6.5)\*1.17 (0.6--2.4)Analyses are done versus delivery ≥ 37 weeks (*n* = 3,724)^\#^Adjusted for maternal age, ethnicity, education, gravidity and smoking with multiple imputationValues are odds ratios (95% confidence interval), \* *P*-value \< 0.05, \*\* *P*-value \< 0.01

The fraction of premature deliveries before 32 and 35 weeks gestation attributable to *C. trachomatis* infection in women was 14.9% (95% CI 4.5--39.5) and 7.4% (95% CI 2.5--20.1), respectively.

### Birthweight {#Sec15}

Crude analysis of differences in birthweight (in grams) between neonates born to chlamydia-positive and chlamydia-negative women showed a significant difference (−114 g \[95% CI −206, −23\]), which disappeared after adjustment for gestational age, maternal age, ethnicity, education, gravidity and smoking (−20 g \[95% CI −98, 58\]). A comparison of low birthweight (*n* = 184) between the two groups also showed no significant difference (unadjusted OR 1.47 \[95% CI 0.8--2.8\]; adjusted OR 0.95, \[0.4--2.2\]). Analysis of the correlation between birthweight, expressed in SDSs, of neonates and their gestational ages according to the maternal chlamydial status is demonstrated in Fig. [3](#Fig3){ref-type="fig"}. This figure suggests that neonates born to chlamydia-positive women had, on average, a lower birthweight SDS, especially when prematurely born. However, the difference did not reach statistical significance; also not after stratification by gestational ages (Table [4](#Tab4){ref-type="table"}). Furthermore, neonates born to chlamydia-positive women were not more often SGA than neonates born to chlamydia-negative women, 3.3% versus 3.6% (*P* = 0.88).Fig. 3Birthweight standard deviation scores (SDS) versus gestational ages of neonates born to women with and without *Chlamydia trachomatis* infectionTable 4Differences in birthweight between neonates born to women with and without *Chlamydia trachomatis* infectionNumber (%)Mean birth weight SDSDifference in birthweight SDS\*UnadjustedAdjusted^\#^*Gestational age*\< 32 weeks (*n* = 22) *C. trachomatis* −18 (82)0.83 *C. trachomatis* +4 (18)−0.72−1.54 (−3.6--0.5)−1.43 (−4.6--1.7)\< 35 weeks (*n* = 64) *C. trachomatis* −57 (89)0.13 *C. trachomatis* +7 (11)−0.87−0.99 (−2.2--0.2)−0.79 (−2.2--0.7)\< 37 weeks (*n* = 190) *C. trachomatis* −180 (95)−0.26 *C. trachomatis* +10 (5)−0.85−0.59 (−1.4--0.2)−0.38 (−1.2--0.4)≥ 37 weeks (*n* = 3,723) *C. trachomatis* −3,583 (96)−0.08 *C. trachomatis* +140 (4)−0.19−0.10 (−0.3--0.1)−0.12 (−0.1--0.3)SDS standard deviation score^\#^Adjusted for maternal age, ethnicity, education, gravidity and smokingDifference and 95% confidence interval calculated with linear regression analysis

Discussion {#Sec16}
==========

This study provides evidence that *C. trachomatis* infection during pregnancy is associated with preterm delivery, but not with low birthweight or being small for gestational age. Young age, Antillean ethnicity and single marital status were independent risk factors for *C. trachomatis* infection in pregnant women.

The strength of this study is its population-based, non-interventional and prospective design with a large number of well-described participants, adjustments for many potential confounders, use of a highly sensitive microbiological test method and near perfect follow-up until delivery (97%).

A potential weakness is that the Generation R cohort is slightly skewed towards a relatively affluent, healthy study population \[[@CR30]\]. However, we do not expect this to affect our results since the study was designed to assess the effects of Chlamydia on pregnancy outcomes in a non-hospital based, low-risk population. Another weakness could be that not all women initially enrolled in the overall study could be tested for *C. trachomatis*. We had a non-response of 9.5% (491 women) for the Chlamydia study. This may in part be true non-response, but is more likely due to a change in the Generation R routine with a later start of inclusion of urine collections for the Chlamydia study. Another 12.0% (621 women) had to be excluded because their urines could not be matched to the respective questionnaires in the database. This was due to logistical problems in the pilot phase of the Chlamydia study. However, all risk factors were similarly distributed among tested and untested women and no differences were found in median gestational age and mean birthweight (39.8 weeks versus 39.8 weeks; *P* = 0.84, 3,408 g versus 3,407 g; *P* = 0.92). Likewise, no differences were observed between chlamydia-positive and negative women regarding the measurement and calculation of gestational age at the prenatal visits. Furthermore, our numbers were too small to assess an association of Chlamydia with miscarriage or perinatal death. Of all enrolled women with *C. trachomatis* results, 62 (1.5%) had a miscarriage or perinatal death. Data on gestational age and birthweight were not available for these deliveries, but likely is that these women delivered relatively more often prematurely. None of these women tested positive for *C. trachomatis*. Theoretically, our effect estimates for associations of chlamydial infection with gestational age and birthweight could be biased and exaggerated when these associations would differ between all fetuses and fetal \`survivors\`. This would be the case if *C. trachomatis* infection would have a \`protective\` effect on early fetal death. However, this is most unlikely \[[@CR8], [@CR20]\].

Previous studies of associations between maternal chlamydial infection and subsequent spontaneous preterm delivery produced mixed results. Most of these studies were small compared to our study (less than 1,000 women included) and were published 10 to over 20 years ago. Early studies were often based on serology, which does not reliably distinguish current from past infection \[[@CR9], [@CR11], [@CR14], [@CR15]\]. One case--control study found an association between the presence of IgM anti-chlamydial antibody and preterm delivery \[[@CR11]\]. Studies using cervical culture for *C. trachomatis* at that time also yielded conflicting results \[[@CR9], [@CR10], [@CR13], [@CR14]\]. More recently, sensitive DNA amplification techniques have been used to screen pregnant women for *C. trachomatis*, but again with contradicting results regarding preterm delivery \[[@CR21]--[@CR24], [@CR34], [@CR35]\]. Using this methodology one case--control study, nested in a USA study among 2,929 pregnant women, reported a two- to three-fold increased risk of preterm delivery before 35 weeks gestation \[[@CR21]\]. Later, the same group reported from an observational study among 2,470 women with bacterial vaginosis or *Trichomonas vaginalis* infection enrolled in a multicentre randomized antibiotic treatment trial that Chlamydia in midterm pregnancy was not associated with increased risk of preterm delivery \[[@CR23]\]. However, most of their chlamydia-positive women were treated between 16--29 weeks gestation. Three more studies in which chlamydia-positive pregnant women were treated also found no association with prematurity or a much lower relative risk for prematurity (1.50) than we found in our study \[[@CR24], [@CR34], [@CR35]\]. In a prospective South-African study among low-risk pregnant women, chlamydia-positive women (cases, *n* = 40) had a relative risk of 2.20 for preterm delivery before 37 weeks gestation (controls, *n* = 303) \[[@CR22]\]. In this study women were also tested for Syphilis, Gonorrhoea and bacterial vaginosis, which were found not to be associated with preterm delivery. Likewise, one of the former studies also found no association between preterm delivery and syphilis, bacterial vaginosis, *Trichomonas vaginalis* and *Neisseria gonorrhoeae* infection \[[@CR35]\]. The true effect of *C. trachomatis* on pregnancy outcomes therefore cannot be fully ascertained from studies in which pregnant women are screened for Chlamydia and treated in the first phases of their pregnancy. In contrast, our study is prospective, non-interventional and population-based (*n* = 4,055), which makes that our findings better estimate the effect of Chlamydia on pregnancy and are more representative for the population as a whole.

Preterm birth represents a major problem for obstetrics and neonatology due to its increasing frequency and accompanying socio-economic impact. We found chlamydial infection to be associated with preterm delivery before 32 and 35 weeks gestation, which was much stronger for the former indicating that Chlamydia contributes relatively more to early than late prematurity. For such an important issue, a four-fold increased risk of preterm delivery before 32 weeks gestation implies that a considerable proportion (14.9% in our cohort) of preterm deliveries before 32 weeks gestation is attributable to chlamydial infection in pregnancy. Despite a considerable confidence interval around the estimate, this would classify *C. trachomatis* among the important infective risk factors of early prematurity. The attributable fraction remained significant (7.4%) for preterm delivery before 35 weeks. It should be noted, however, that the number and proportion of premature deliveries attributable to Chlamydia highly depends upon the *C. trachomatis* prevalence in a given population, and that some residual confounding as a result of co-infection by other genitourinary pathogens cannot be excluded. Another limitation could be that we did not correct for other potential risk factors as previous preterm delivery, since we did not have such data, and previous termination of pregnancy in these women since this potential confounder was only recently established \[[@CR36]\]. Importantly, we had no information concerning the use of (macrolide) antibiotics during pregnancy, but suggest that this would mitigate, rather than exaggerate, the effect of Chlamydia on pregnancy outcome. The latter information would have been interesting since early treatment may prevent preterm birth (34, 35). Finally, pregnant women are not routinely tested and treated for *Ureaplasma urealyticum* or *Mycoplasma genitalium* in the Netherlands and neither are women with premature rupture of the membranes routinely treated with antibiotics.

Extrapolation of our findings to the Netherlands, where approximately 3,000 neonates are born before 32 weeks gestation annually \[[@CR37]\], showed that *C. trachomatis* infection in pregnancy contributes approximately 450 cases to this burden; for deliveries before 35 weeks gestation these numbers are 7,100 and 525, respectively. Our finding of an association between *C. trachomatis* infection and premature delivery may be useful in a cost-benefit analysis of Chlamydia screening during pregnancy.

Interestingly, *C. trachomatis* infection was more prevalent among women who had twins than those who had singletons, a finding not reported before. Since Chlamydia is associated with infertility and assisted conception for infertility is associated with twin pregnancies, an explanation for our findings may be that chlamydia-positive women were not treated effectively during their infertility work-up or that they were reinfected. This observation warrants further study into medical histories of women with twin deliveries versus women with singletons.

The major risk factors we found are amongst the many previously described including young age, urban residence, low socio-economic class, specific ethnic groups, single marital status and recent changes in sexual partnerships or sexual promiscuity \[[@CR9], [@CR26], [@CR38], [@CR39]\]. Adolescents are at highest risk of infection, which was also observed in this study \[[@CR27]\]. We could not evaluate urban residence since all participating women resided in Rotterdam. The risk factors we found are similar to those reported in another Dutch community-based study \[[@CR28], [@CR40]\]. Importantly, *C. trachomatis* prevalences vary widely \[[@CR26]\], which will directly affect the incidence of complications attributable to this infection, including preterm delivery.

One may question the design of our study since women screened and found positive for *C. trachomatis* were not treated. The design of our study would face ethical barriers in countries that have national guidelines or directives advocating Chlamydia screening and treatment in the routine of antenatal care, and would be impossible to perform \[[@CR41], [@CR42]\]. However, in most countries of the European Union, including the Netherlands, screening and treatment for Chlamydia during pregnancy remains controversial and is currently not recommended in routine antenatal care \[[@CR43], [@CR44]\]. Our study provides novel data that may well have an impact on the future antenatal screening strategy in the Netherlands and elsewhere. In addition, Generation R was designed as a non-interventional follow-up study \[[@CR29], [@CR30]\]. All following substudies, including ours, had to fit into this overall design. Furthermore, Generation R provided the data anonymously to protect the privacy of participants. We, therefore, had no access to names or addresses of chlamydia-positive women.

In conclusion, *C. trachomatis* urogenital infection in pregnant women increases the risk of preterm delivery, especially early prematurity, such that a significant proportion of preterm deliveries can be attributed to this infection. In order to improve birth outcomes, health systems should consider additional focus on *C. trachomatis* infection, especially in young women and others at increased risk.
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